Clinical TrialNeurological InjuryPsilocybinPsilocybinRecruiting

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM)

Open-label, randomised Phase I trial (n=20) assessing safety and tolerability of single 25 mg or split 12.5 mg+12.5 mg oral psilocybin in people with chronic stroke; secondary outcomes explore motor recovery.

Target Enrollment
20 participants
Study Type
Phase I interventional
Design
Randomized

Detailed Description

This Phase I study evaluates safety and tolerability of psilocybin administered as either a single 25 mg dose or a split 12.5 mg + 12.5 mg dose (second dose 2 hours later) in individuals at least 12 months post-ischemic or haemorrhagic stroke.

Secondary objectives include exploratory assessment of psilocybin's potential to enhance motor recovery after stroke, informed by preclinical data suggesting psychedelics may reopen critical periods for learning.

Study Protocol

Preparation

sessions

Dosing

1 sessions

Integration

sessions

Study Arms & Interventions

25 mg

experimental

Single 25 mg oral psilocybin dose.

Interventions

  • Psilocybin25 mg
    via Oral• single dose• 1 doses total

12.5+12.5 mg

experimental

Split dose: 12.5 mg followed by 12.5 mg two hours later.

Interventions

  • Psilocybin12.5 mg
    via Oral• single dose (split)• 2 doses total

    Second 12.5 mg given 2 hours after first.

Participants

Ages
18 – 99
Sexes
Male & Female

Inclusion Criteria

  • Inclusion Criteria:
  • Over age 18 years, inclusive.
  • Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date.
  • Ability to give informed consent and understand the tasks involved.
  • Agree that, for the study duration, will refrain from: (1) no new prescription medications during the time of the study without approval of the study team; (2) taking any herbal supplement (except with prior approval of the research team); (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs, 2. acetaminophen, 3. vitamins, 4. or other over-the-counter medications approved by the research team.
  • Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration.
  • Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocybin.
  • Are willing to be contacted via telephone for all necessary telephone contacts.
  • Must have a negative pregnancy test if able to bear children.
  • Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.
  • Must agree to inform the investigators within 48 hours of any new medical conditions and procedures.
  • Are proficient in speaking and reading English.
  • Agree to have all clinical visit sessions recorded to audio and video.
  • Agree to not participate in any other interventional clinical trials during the duration of this study.

Exclusion Criteria

  • Exclusion Criteria:
  • Taking one of the following medications in the 30 days prior to psilocybin administration: selective serotonin reuptake inhibitor (SSRI); serotonin-norepinephrine reuptake inhibitors (SNRI); bupropion; valproic acid; zolpidem; trazodone; carbamazepine; tricyclic antidepressants; monoamine oxidase inhibitors; mirtazapine; lithium; buspirone; atypical antipsychotics; clonazepam; gabapentin; lamotrigine; levetiracetam; phenobarbital; phenytoin; topiramate; valproic acid; zonisamide.
  • History of medically significant suicide attempt.
  • Evidence of acute cardiac dysfunction as evidenced by either elevated troponin or EKG changes within 48 hours of administration.
  • Systolic blood pressure that is greater than 150 mmHg on > 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.
  • Diastolic blood pressure that is greater than 100 mmHg on > 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.
  • Systolic blood pressure is less than 90 mmHg on > 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.
  • Diastolic blood pressure is less than 30 mmHg on > 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.
  • Systolic blood pressure exceeds 160 mmHg or is less than 90 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.
  • Diastolic blood pressure exceeds 100 mmHg or is less than 30 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.
  • Cognitive impairment that, in the estimation of the study team, would preclude the use of the MindPod Dolphin.
  • History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).
  • Social and/or personal circumstances that interfere with ability to perform follow up assessments.
  • Are pregnant or nursing.
  • Weigh less than 48 kg.
  • Are not able to give adequate informed consent.
  • Are actively abusing opioids, cocaine, phencyclidine (PCP), amphetamines, or alcohol.
  • SCID-5 criteria for moderate or severe substance use disorder.
  • Diagnosis of schizophrenia, history of prior psychosis, anxiety requiring hospitalization, or Type 1 bipolar disorder.
  • Hypernatremia.
  • Hypokalemia (but can have received repletion during the prior 24 hours).
  • Hyperkalemia.
  • Glomerular filtration rate of < 30 ml/min.
  • Elevated white blood cell count.
  • Hemoglobin < 7 g/dl.
  • Platelet count < 100,000 g/dl.
  • Acute cardiac dysfunction demonstrated by either troponin elevation (chronic elevation is acceptable), or EKG changes suggestive of acute coronary syndrome.
  • Active suicidal ideation as assessed by the C-SSRS.

Study Details

Locations

Johns Hopkins — Baltimore, Maryland, United States

Your Library